{"schema_version":"secwatch.filing_event.v1","accession":"0001665988-26-000029","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2026-05-21T20:58:18+00:00","discovered_at":"2026-05-21T20:59:00.279763+00:00","generated_at":"2026-05-21T21:01:18.775768+00:00","sec_items":["7.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance","bullets":["FDA reclassified non-invasive bone growth stimulators, including Bioventus' Exogen Ultrasound Bone Healing System, from Class III to Class II on April 16, 2026.","CMS updated Medicare fee schedule for HCPCS codes E0747, E0748, and E0760 for services on or after May 18, 2026.","Bioventus does not expect material impact from reimbursement rate changes on its FY2026 financial results.","Company reiterates previously issued 2026 financial guidance despite the regulatory changes.","Bioventus continues to evaluate long-term impact; future CMS actions could require revised outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001665988-26-000029","json":"https://secwatch.observer/filing/0001665988-26-000029.json","markdown":"https://secwatch.observer/filing/0001665988-26-000029.md","text":"https://secwatch.observer/filing/0001665988-26-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/0001665988-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/bvs-20260521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-21T21:01:18.775768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001698530-26-000060","ticker":"XCUR","company_name":"EXICURE, INC.","filed_at":"2026-06-01T19:30:08+00:00","headline":"Exicure gets Nasdaq delinquency notice for late 10-Q; files next day, says compliance regained","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same SEC item: 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-26-000060","json":"https://secwatch.observer/filing/0001698530-26-000060.json","markdown":"https://secwatch.observer/filing/0001698530-26-000060.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853026000060/0001698530-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853026000060/xcur-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-054956","ticker":"MSS","company_name":"Maison Solutions Inc.","filed_at":"2026-05-12T17:22:23+00:00","headline":"Maison Solutions regains Nasdaq minimum bid price compliance; listing continues","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same SEC item: 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054956","json":"https://secwatch.observer/filing/0001213900-26-054956.json","markdown":"https://secwatch.observer/filing/0001213900-26-054956.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1892292/000121390026054956/0001213900-26-054956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1892292/000121390026054956/ea0290261-8k_maison.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-023560","ticker":"NJR","company_name":"NEW JERSEY RESOURCES CORP","filed_at":"2026-06-01T20:03:21+00:00","headline":"NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023560","json":"https://secwatch.observer/filing/0001140361-26-023560.json","markdown":"https://secwatch.observer/filing/0001140361-26-023560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/0001140361-26-023560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/ef20075084_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026519","ticker":"ELTP","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-06-01T11:00:24+00:00","headline":"Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026519","json":"https://secwatch.observer/filing/0001493152-26-026519.json","markdown":"https://secwatch.observer/filing/0001493152-26-026519.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/0001493152-26-026519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068002","ticker":"REPL","company_name":"Replimune Group, Inc.","filed_at":"2026-05-29T13:56:10+00:00","headline":"Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068002","json":"https://secwatch.observer/filing/0001104659-26-068002.json","markdown":"https://secwatch.observer/filing/0001104659-26-068002.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/0001104659-26-068002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/tm2615980d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039005","ticker":"BDX","company_name":"BECTON DICKINSON & CO","filed_at":"2026-05-29T12:39:28+00:00","headline":"BD resumes ChloraPrep shipments after voluntary hold; all final release testing acceptable","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 7.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039005","json":"https://secwatch.observer/filing/0001628280-26-039005.json","markdown":"https://secwatch.observer/filing/0001628280-26-039005.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000162828026039005/0001628280-26-039005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000162828026039005/bdx-20260529.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}